ASCLF

Healthcare Biotechnology

Ascletis Pharma Inc.

$1.04

-0.08 -7.14% today

Price History

Not enough data

Key Stats

Market Cap

1.09B

Avg Volume

724

EPS

-$0.09

52W High

$2.50

52W Low

$1.04

Div. Yield

0.0%

Valuation

P/B Ratio

3.20

P/S Ratio

1155.29

EV/EBITDA

1.73

EV/Revenue

-1252.77

Margins

Gross Margin 42.9%

Operating Margin (73801.5%)

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Return on Equity

(28.6%)

Return on Assets

(19.6%)

Liquidity & Leverage

Current Ratio

12.92

Quick Ratio

12.88

Debt / Equity

0.00

Total Cash

2.27B

Total Debt

3.74M

About

Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company's commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Further, it offers ASC30, for obesity; ASC47 for muscle-preserving weight loss treatment; and ASC39, a potent and amylin-selective oral small molecule amylin receptor agonist. Ascletis Pharma Inc. was founded in 2013 and is based in Wan Chai, Hong Kong.